Journal of Peking University (Health Sciences) ›› 2026, Vol. 58 ›› Issue (3): 674-677. doi: 10.19723/j.issn.1671-167X.2026.03.031

Previous Articles    

高鹏1, 刘燕玲1, 李俊峰2, 姚立琼1,*()   

  • Received:2024-07-05 Online:2026-06-18 Published:2026-04-23
  • Contact: 姚立琼
  • Supported by:
    the National Science Foundation of China(81800528)

RICH HTML

  

CLC Number: 

  • R512.62

Table 1

Effects of different genotypes hepatitis B virus (HBV) on Th17 and Treg cells and their ratios in the normal alanine aminotransferase (ALT) group"

Items B type C type t P
n 35 38
HBV DNA 5.097±1.116 5.279±1.299 -0.637 0.526
Th17/% 1.818±0.112 1.832±0.123 -0.491 0.625
Treg/% 4.865±0.196 4.918±0.168 -1.242 0.218
Th17/Treg 0.374±0.026 0.373±0.02 -0.206 0.837

Table 2

Effects of different genotypes hepatitis B virus (HBV) on Th17 and Treg cells and their ratios in the alanine aminotransferase (ALT) < 2 times the normal upper limit group (the ALT>normal upper limit)"

Items B type C type t P
n 37 35
HBV DNA 5.330±1.139 5.247±1.260 0.290 0.773
Th17/% 2.560±0.347 2.525±0.348 0.426 0.671
Treg/% 5.501±0.404 5.513±0.356 -0.134 0.893
Th17/Treg 0.468±0.073 0.461±0.074 0.435 0.665

Table 3

Effects of different genotypes hepatiti B virus (HBV) on Th17 and Treg cells and their ratios in the alanine aminotransferase (ALT) ≥ 2 fold upper limit group"

Items B type C type t P
n 38 37
HBV DNA 5.331±1.190 5.451±1.145 -0.445 0.658
Th17/% 3.970±0.537 4.718±0.591 -5.733 <0.001
Treg/% 5.967±0.320 6.543±0.416 -6.724 <0.001
Th17/Treg 0.667±0.095 0.724±0.102 -2.506 0.014
1
Zamor PJ , Lane AM . Interpretation of HBV serologies[J]. Clin Liver Dis, 2021, 25 (4): 689- 709.

doi: 10.1016/j.cld.2021.06.012
2
Pollicino T , Caminiti G . HBV-integration studies in the clinic: Role in the natural history of infection[J]. Viruses, 2021, 13 (3): 368.

doi: 10.3390/v13030368
3
Bello KE , Mat Jusoh TNA , Irekeola AA , et al. A recent prevalence of hepatitis B virus (HBV) genotypes and subtypes in Asia: A systematic review and meta-analysis[J]. Healthcare, 2023, 11 (7): 1011- 1018.

doi: 10.3390/healthcare11071011
4
Gu Y , Li X , Gu L , et al. An immuno-clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B[J]. Aging, 2020, 12 (24): 26063- 26079.

doi: 10.18632/aging.202274
5
Li K , Liu H , Guo T . Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients[J]. Clin Res Hepatol Gastroenterol, 2017, 41 (4): 399- 407.

doi: 10.1016/j.clinre.2016.12.004
6
Jose-Abrego A , Roman S , Laguna-Meraz S , et al. Host and HBV interactions and their potential impact on clinical outcomes[J]. Pathogens, 2023, 12 (9): 1146- 1152.

doi: 10.3390/pathogens12091146
7
Nicolini LA , Orsi A , Tatarelli P , et al. A global view to HBV chronic infection: Evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals[J]. Int J Environ Res Public Health, 2019, 16 (18): 3307.

doi: 10.3390/ijerph16183307
8
Hogan S , Page A , Dixit S , et al. HBV prevalence in Sub-continental countries: A systematic review and meta-analysis[J]. PLoS One, 2023, 18 (12): e0295670.
9
Chen J , Li L , Yin Q , et al. A review of epidemiology and clinical relevance of hepatitis B virus genotypes and subgenotypes[J]. Clin Res Hepatol Gastroenterol, 2023, 47 (7): 102180.

doi: 10.1016/j.clinre.2023.102180
10
Wang L , Zeng X , Wang Z , et al. Recent advances in understanding T cell activation and exhaustion during HBV infection[J]. Virol Sin, 2023, 38 (6): 851- 859.

doi: 10.1016/j.virs.2023.10.007
11
Wan Z , Zhou Z , Liu Y , et al. Regulatory T cells and T helper 17 cells in viral infection[J]. Scand J Immunol, 2020, 91 (5): e12873.

doi: 10.1111/sji.12873
12
高鹏, 雒艳萍. 乙型肝炎病毒在不同丙氨酸氨基转移酶状态下对Th17、Treg细胞及其比率的影响[J]. 北京大学学报(医学版), 2022, 54 (2): 272- 277.

doi: 10.19723/j.issn.1671-167X.2022.02.012
13
Beňová K , Hancková M , Koći K , et al. T cells and their function in the immune response to viruses[J]. Acta Virol, 2020, 64 (2): 131- 143.

doi: 10.4149/av_2020_203
14
Cui D , Jiang D , Yan C , et al. Immune checkpoint molecules expressed on CD4+ T cell subsets in chronic asymptomatic hepatitis B virus carriers with hepatitis B e antigen-negative[J]. Front Microbiol, 2022, 13, 887408.

doi: 10.3389/fmicb.2022.887408
15
Xu J , Zhan Q , Fan Y , et al. Human genetic susceptibility to hepatitis B virus infection[J]. Infect Genet Evol, 2021, 87, 104663.
16
Revill PA , Tu T , Netter HJ , et al. The evolution and clinical impact of hepatitis B virus genome diversity[J]. Nat Rev Gastroenterol Hepatol, 2020, 17 (10): 618- 634.
17
Fernandes da Silva C , Keeshan A , Cooper C . Hepatitis B virus genotypes influence clinical outcomes: A review[J]. Can Liver J, 2023, 6 (3): 347- 352.
18
Likhitsup A , Lok AS . Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials[J]. Clin Liver Dis, 2019, 23 (3): 401- 416.
[1] GAO Peng,LUO Yan-ping,LI Jun-feng,CHEN lin,MAO Xiao-rong. Effects of hepatitis B virus on Th17, Treg and Th17/Treg ratio in different alanine aminetransferase stages [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 272-277.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!